Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anthony P. Cammarata"'
Autor:
Christopher M Rubino, Anthony P Cammarata, Paul Ambrose, Pete Schmidt, Myra Popejoy, Jean Gong, Xia Pu
Publikováno v:
Open Forum Infectious Diseases. 9
Background ADI is a fully human IgG1 monoclonal antibody engineered to have an extended half-life with high potency and broad neutralization against SARS-CoV-2 and other SARS-like coronaviruses with pandemic potential. Our objective was to develop a
Autor:
Sujata M Bhavnani, Christopher M Rubino, Jeffrey P Hammel, Anthony P Cammarata, Kajal Larson, Kathryn Liolios, Sarah McLeod, Alita Miller, Paul G Ambrose, Ruben Tommasi, John O'Donnell
Publikováno v:
Open Forum Infectious Diseases. 9
Background SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, which are often severe and associated with substantial mortality. PPK, PTA, and clinical PK/PD analyses were conducted using all
Autor:
Sebastian Schröpf, Anthony P. Cammarata, Kamal Hamed, Mark J Polak, Karine Litherland, Anne Smits, Christopher M. Rubino
Publikováno v:
Antimicrobial Agents and Chemotherapy
Ceftobiprole is an advanced-generation cephalosporin for intravenous administration with activity against Gram-positive and Gram-negative organisms. A population pharmacokinetic (PK) model characterizing the disposition of ceftobiprole in plasma usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93df92573d8679313762b166f149487a
https://lirias.kuleuven.be/handle/123456789/683977
https://lirias.kuleuven.be/handle/123456789/683977